VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced changes to its Board of Directors effective immediately. Janusz Grabski has resigned from the Board, and Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, has been formally appointed as a director. The appointment follows the Board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
These changes are intended to ensure that the Board continues to meet Helix's evolving governance and capital markets requirements and has the composition and experience needed to support the company's clinical development and broader corporate objectives. The Board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in future endeavors.
Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
The appointment of Dr. Mehrling to the Board is significant as it aligns leadership with governance, potentially streamlining decision-making and reinforcing strategic direction. Dr. Mehrling's dual role as CEO and director may enhance the Board's insight into clinical and operational matters, which is crucial as the company advances its pipeline.
This board restructuring comes at a pivotal time for Helix, as the company continues to develop its lead candidate L-DOS47 for NSCLC, a cancer with high unmet medical need. The inclusion of the CEO on the board could facilitate more cohesive execution of corporate objectives and improve communication between management and the board.
Investors and stakeholders may view this as a positive step towards strengthening governance, especially as Helix navigates the complexities of clinical development and potential capital raises. The changes could also signal a commitment to maintaining a board composition that meets the evolving needs of the company in the competitive oncology landscape.
The company's shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, visit Helix BioPharma's website.
These board changes are part of Helix's broader efforts to position itself for success in advancing its innovative cancer therapies. The appointment of Dr. Mehrling to the board underscores the company's focus on aligning leadership with its strategic goals, which could have implications for its clinical programs and future growth.
